Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree. It was a shit show for many years but also provide investment opportunities. Hopefully, the new CEO can turn things around.
I did not even know NEVDF exist when it hit 5c and under. LOL That was a good add! I got in last Friday.
From my point of view, the management was confident to get the financing done. I think both of us need to read the technical report
https://nevadacopper.com/projects/technical-reports/
You are right! I just hope they can update the homepage. How the f*** Jim the pump and dump is there?
Looks like none dilutive financing to me! Going to $0.10 soon! I should have taken out all the 0.0653 ask yesterday!
Nevada Copper Provides Financing Update
November 24, 2020 17:53 ET | Source: Nevada Copper Corp.
YERINGTON, Nev., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Nevada Copper Corp. (TSX: NCU) (“Nevada Copper” or the “Company’’) is pleased to announce that it has agreed to non-binding terms with its senior lender, KfW IPEX-Bank GMBH (“KfW”) and is engaged in ongoing discussions with other lenders to provide a combined financing package of at least US$30 million. The Company is working with KfW and the other lenders with the aim of executing binding agreements for loan facilities and being able to receive funding thereunder by the end of 2020.
The proposed financing package will provide substantial additional liquidity for Nevada Copper as it ramps-up operations into 2021. Under the non-binding term sheet with KfW, it is proposed that KfW will provide a new US$15 million senior loan, with a three-year tenor, at an interest rate of LIBOR plus 4.9%. This new KfW loan is expected to have a 12-month repayment holiday period. In addition, amortization and debt service account payments under the Company’s existing senior project loan facility with KfW are expected to be deferred until 2023. The Company is also in the process of finalizing the specific terms of an additional complementary financing from other lenders and will provide an update in due course.
The proposed combined financing package is subject to, amongst other things, finalization of terms with KfW and the other lenders, negotiation and execution of definitive documentation, satisfaction of conditions precedent and regulatory approval, if required.
As previously announced on November 10, 2020, Pala Investments Limited (“Pala”), the Company’s largest shareholder, confirmed that it will continue to provide financial support to the Company until the end of the year, by which time the Company expects to complete the new financing package. In connection with this, Pala has provided the Company with access to additional liquidity of up to US$15 million in the form of a promissory note (the “Promissory Note”). The Company made an initial draw of US$2 million under the Promissory Note, with subsequent draws available at the Company’s option, subject to agreed use of proceeds. The Promissory Note has a maturity date of January 31, 2021, bears interest at 8% per annum on amounts drawn, and is expected to be repaid through the funds received from the US$30 million financing package as outlined above. The negotiation and approval of the Promissory Note was supervised on behalf of the Company by the independent members of the Company’s board of directors.
There can be no assurance that the definitive binding agreements for the proposed financing package as outlined above will be entered into or that those transactions will be completed. If the financing package is not completed, then absent obtaining other financing, the Company may not be able to continue operations.
About Nevada Copper
http://www.globenewswire.com/news-release/2020/11/24/2133258/0/en/Nevada-Copper-Provides-Financing-Update.html
Bid at 7c now. It is very undervalued considering the mine is operational
Mind explain the reason?
Lawyers will seek us if they really take the co private at a ridiculous price.
The premium was not much but they still paid a 2 year high price of $2.9. Stock was squeezed to $3.09 that day. I would take the money and run.
You missed this part. That was why I said it was not bad
I totally agree with you on this. This is why we are still trading at 6c for a running copper mine!
It looks pretty good for Avoca Resources Limited, an Australian gold miner. I am not too worried. It is a US mine, Russian oligarch can do no shit. Or they will eat the lawsuit.
https://finance.yahoo.com/quote/ASR.TO/chart?p=ASR.TO
https://en.wikipedia.org/wiki/Avoca_Resources_Limited#cite_note-17
At least AMR is still public. I think because they are Russian Oligarch, they probably want to avoid being too aggressive with a US asset.
http://asianmineralres.com/
Anyway, the rewards are still pretty good investing in an almost uprunning copper mine during an EV boom
They have quite a bit track record
http://www.pala.com/en/track-record/case-studies.html
You are right. Pala did kill Cobalt 27. But Cobalt 27 is not a miner. The price of Cobalt crashed after the 2018 peak. Seems a fair value Pala paid
https://tradingeconomics.com/commodity/cobalt
https://seekingalpha.com/news/3472093-cobalt-27-to-be-bought-p-e-firm-in-c-501m-deal
https://finance.yahoo.com/news/anson-funds-supports-improvements-cobalt-154142029.html
Found this one but Pala was the victim
https://www.reuters.com/article/castle-harlan-bid-rigging/buyout-firm-flipped-company-in-one-day-australian-court-hears-idUSL3E8MC0YD20121112
I agree it is a possibility since the share price is really low right now.
Do you know if Pala Investments Ltd has done such things before?
I am going to do some DD on that if nobody ever checked.
My king, China/Hongkong plays are going to be hot again with the Biden administration (also the crackdown of Hongkong street riots).
GTNM and YSGG are both Robert Chin shells trading at similar Market Cap and acquired around the same time.
https://investorshub.advfn.com/1399-Internet-Tech-App-Gr-Inc-YSGG-13735/
The address 610 Nathan Rd, Hong Kong is a high-profile office building in Hongkong. It is likely to be a Hongkong office for some Chinese companies.
For example
http://www.shuangxu-tec.com/index.php?m=content&c=index&a=lists&catid=84
Too bad they did not list the office number with the transfer agent.
China and Hongkong plays are going to be hot after all the political turmoil is settled down
YSGG is 1399 in Cantonese. I am wondering if that is a Chinese Crypto company merged in. Transfer agent data shows that too.
https://www.transferonline.com/AboutUs/ClientDetail/1399-Internet-Technology-Application-Group-Inc-
ROBERT CHIN filed this year's annual list
08/31/2020 08/31/2020 20200883927 Annual List
Also, more insider buys than sells for the past year
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159107573
Pala Investments Ltd who is a large investor in NCU and holds lots of commons and warrants controls 4 seats in the board. https://nevadacopper.com/corporate/directors/
I mean $100. $1000 maybe in 10 years. LOL
Good call. I got my position today. Will double down if they dilute for the 20~30m loan.
If they can figure out a way to uplist us to Nasdaq or Amex, FOMO from RH and Webull will push us close to $1000.
OS only 2m with Netcapital mergered in!
Double digits soon!
It should go back to PM high. They always do!
Where is everyone? All sold for a loss? LOL
A lot of institutions adding their holding recently. Even after Covid19 is gone, BRL under Cohen should be able to make cash flow positive for OPK. Then by end of 2021, PFE loyalty comes in.
I am riding along with SABBY MANAGEMENT LLC. Hope they can pull another Co_dx here!
Calcifediol and corticosteroids, the latest prescription against Covid-19
The Reina Sofía Hospital has shown in a first study that the administration of calcifediol , a drug prescribed for other diseases that have nothing to do with Covid-19 (generally bone ailments) , helps alleviate the most serious consequences of infection by the coronavirus.
One of the authors of the study, José Manuel Quesada - investigator of the Imibic - clarifies that the calcifediol does not prevent contagion nor cure the disease. What it does, he explains, is to turn Covid-19 into “a minor disease such as the flu, a not too serious viral phenomenon. It makes you go through a few bad days but it doesn't kill you ».
To understand how calcifediol works , you first need to know a term that is often mentioned, but not always well understood, during the pandemic: "cytokine storms . " In severe cases of Covid-19 infection, what kills or leads a patient is not the virus, but - strange as it sounds - the person's own body.
On certain occasions, and without really knowing the reasons, the immune system overreacts to the presence of a foreign body such as the Covid-19 coronavirus (it also does so with other pathogens). It kills the virus, but also healthy tissue. It's like killing flies with cannon shots : in the end you end up hitting who you shouldn't.
What are cytokines?
Cytokines play an essential role in this process. They are varied proteins that the immune system generates to carry out different tasks. One of them is to direct the immune cells , our "soldiers" in case of attack, to the exact place where the problem is. They also activate or deactivate tissue inflammation , a natural response of the human body to an attack. If things get nasty, they can command immune cells to make more cytokines to intensify the response.
Under normal conditions, that cycle is always under control. But on rare occasions, the immune system goes haywire and nothing stops the production of these proteins, which end up accumulating in vital tissues and organs. That's a "cytokine storm." The researcher Quesada describes its effects on Covid-19 patients as follows: "It is so brutal that the lungs get flooded and as oxygen does not enter the lungs, people go to the ICU" to be able to stay alive.
This is where calcifediol comes into play . One of its effects is, indicates Quesada, "to prevent an exaggerated response from the immune system." What this drug does is therefore not to enhance the natural defenses of the human being, but to "modulate" them. And that is "the key", continues the researcher: " We have hit the right key but we will have to continue investigating."
Until now, calcifediol had been used in combination with azithromycin , a broad-spectrum antibiotic that, like all antibiotics, alone is of no use against a viral attack. But it had been used to treat certain respiratory conditions in combination with other substances. "Of every 100 people with our treatment, only three went to the ICU, while among those who did not take it, 50 percent were admitted ", recalls the researcher.
A new way
This situation has changed and, as José Manuel Quesada points out, research is focused on using calcifediol with what in medical jargon is called "the best available treatment" , which are now corticosteroids , powerful anti-inflammatory drugs that limit adverse effects of the "cytokine storm." In combination with the drug tested by the Reina Sofía, an adequate immune system response could be achieved for Covid-19.
Now it remains to show that this combination of calcifediol and corticiodes works, for which "we will need a very large number of patients " in a later phase of the study, clarifies the Imibic researcher . Like everything in science, it is necessary to test and experiment before giving a result for certain, but Quesada is confident that calcifediol will end up being part of the definitive cocktail of drugs against Covid-19 while waiting for the vaccine.
https://sevilla.abc.es/andalucia/cordoba/sevi-coronavirus-cordoba-colcifediol-y-corticoides-ultima-receta-contra-covid-19-202010021949_noticia.html#vca=mod-sugeridos-p2&vmc=relacionados&vso=calcifediol-y-corticoides-la-ultima-receta-contra-el-covid-19&vli=noticia.foto.andalucia
Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study
Got a starter position
Ticker changes to NCPL the first week of Dec. We should see some pumping after that.